Welcome to our dedicated page for Alr Technologies news (Ticker: ALRTF), a resource for investors and traders seeking the latest updates and insights on Alr Technologies stock.
ALR Technologies SG Ltd. (OTCQB: ALRTF) delivers innovative diabetes management solutions through its FDA-cleared ALRT Diabetes Solution and GluCurve Pet CGM for companion animals. This page provides essential updates for tracking the company's progress in human and veterinary care.
Access timely announcements including clinical study results, regulatory milestones, intellectual property developments, and partnership opportunities. Key focus areas include the Predictive A1c algorithm's implementation and veterinary treatment optimization through continuous glucose monitoring technology.
Discover updates on ALRTF's dual-market strategy, from recent patent grants to real-world application data. Our curated news collection serves investors and healthcare professionals seeking to monitor advancements in diabetes care innovation.
Bookmark this page for structured access to ALR Technologies' official communications, including treatment efficacy studies and strategic initiatives across both human and animal health sectors.
Covetrus will showcase its innovative technologies, including Pulse, the first cloud-based veterinary operating system, and the GluCurve Pet CGM, a continuous glucose monitoring system for diabetic pets, at VMX 2023 from January 14-18 in Orlando, Florida. Covetrus aims to address industry challenges through these offerings and will hold educational seminars focusing on practice management. The company also entered a co-branded distribution agreement with ALR Technologies SG Ltd (ALRTF) to enhance the availability of the GluCurve Pet CGM.
ALR Technologies SG Ltd. (OTCQB:ALRTF) has secured a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for distributing Continuous Glucose Monitor (CGM) hardware in the animal health market. This exclusive deal is expected to boost product availability and sales significantly in 2023. For December and Q4 2022, ALRT anticipates sales between $145,000 and $155,000, with Q1 2023 projected at $450,000 to $600,000. The company plans to increase production capacity and will showcase GluCurve at upcoming expos to enhance market visibility.
FAQ
What is the current stock price of Alr Technologies (ALRTF)?
What is the market cap of Alr Technologies (ALRTF)?
